| Description | UW Pathology Presents “Building a Global, Multi-Product Biotechnology Company"
Clay Siegall, PhD
President & CEO
Seagen Inc
Why Attend this Seminar?
Seagen (formerly Seattle Genetics) started operations in 1998 with a vision to improve the lives of people with cancer through innovative targeted therapies. Today, the company is the global leader in antibody-drug conjugates, a technology that utilizes the targeting power of antibodies to deliver small molecule drugs to the tumor. Seagen is marketing three approved cancer medicines, conducting broad clinical development of these programs, advancing a deep pipeline of other novel agents in clinical and preclinical development and growing beyond its current staff of more than 2,200 people in the U.S., Canada and Europe. In this seminar, Clay Siegall, Ph.D., President, CEO and co-founder of Seagen, will discuss the company’s evolution and its future opportunities to address the unmet medical needs of cancer patients.
Meeting ID: 922 0180 0473
Passcode: 520 |
|---|